GLUT-1 as a receptor for HTLV envelopes and its uses
AssigneesCentre National de la Recherche Scientifique (CNRS), Universite De Montpellier 2
InventorsJean-Luc Battini, Nicolas Manel, Felix Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
Life of this patent
Estimating the term…
Abstract
The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.
Claims17
An isolated fusion polypeptide, wherein said fusion polypeptide consist of a soluble receptor binding domain (RBD) ligand derived from the soluble part of the glycoprotein of the human T-cell leukemia virus (HTLV-2) binding to the Glucose Transporter 1 (GLUT1), consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 7, SEQ ID NO:
- 43, and fragments of SEQ ID NO:
- 4 or SEQ ID NO:
- 43,
- wherein said fragments of SEQ ID NO:
- 43 are polypeptides delimited in their N-terminal extremity by the amino acid located in position 1 to 90 and in their C-terminal extremity by the amino acid located in position 135 to 245 of SEQ ID NO:
- 43;
- and
- wherein said fragments of SEQ ID NO:
- 4 consist of amino acids 19 to 224 of SEQ ID NO:
- 4, or 20 to 224 of SEQ ID NO:
- 4, or 21 to 224 of SEQ ID NO:
- 4, or 19 to 178 of SEQ ID NO:
- 4, or 20to 178 of SEQ ID NO:
- 4, or 21 to 178 of SEQ ID NO:
- 4, and
- wherein said isolated polypeptide is chemically modified to add a fluorochrome or a fluorescent compound.
An isolated fusion polypeptide, wherein said fusion polypeptide consists of:
- a soluble receptor binding domain (RBD) ligand derived from the soluble part of the glycoprotein of the human T-cell leukemia virus (HTLV-2) binding to the Glucose Transporter 1 (GLUT1), consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 7, SEQ ID NO:
- 43, and fragments of SEQ ID NO:
- 4 or SEQ ID NO:
- 43,
- wherein said fragments of SEQ ID NO:
- 43 are polypeptides delimited in their N-terminal extremity by the amino acid located in position 1 to 90 and in their C-terminal extremity by the amino acid located in position 135 to 245 of SEQ ID NO:
- 43, and
- wherein said fragments of SEQ ID NO:
- 4 consist of amino acids 19 to 224 of SEQ ID NO:
- 4, or 20 to 224 of SEQ ID NO:
- 4, or 21 to 224 of SEQ ID NO:
- 4, or 19 to 178 of SEQ ID NO:
- 4, or 20 to 178 of SEQ ID NO:
- 4, or 21 to 178 of SEQ ID NO:
- 4;
- and
- a Tag, an antibody constant fragment, or a fluorescent protein.
A composition comprising at least one isolated fusion polypeptide, wherein said fusion polypeptide consists of:
- a soluble receptor binding domain (RBD) ligand derived from the soluble part of the glycoprotein of the human T-cell leukemia virus (HTLV-2) binding to the Glucose Transporter 1 (GLUT1), consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 7, SEQ ID NO:
- 43, and fragments of SEQ ID NO:
- 4 or SEQ ID NO:
- 43,
- wherein said fragments of SEQ ID NO:
- 43 are polypeptides delimited in their N-terminal extremity by the amino acid located in position 1 to 90 and in their C-terminal extremity by the amino acid located in position 135 to 245 of SEQ ID NO:
- 43;
- and
- wherein said fragments of SEQ ID NO:
- 4 consist of amino acids 19 to 224 of SEQ ID NO:
- 4, or 20 to 224 of SEQ ID NO:
- 4, or 21 to 224 of SEQ ID NO:
- 4, or 19 to 178 of SEQ ID NO:
- 4, or 20 to 178 of SEQ ID NO:
- 4, or 21 to 178 of SEQ ID NO:
- 4;
- and
- a Tag, an antibody constant fragment, or a fluorescent protein.
Dependencies are inferred from the claim text.